Regeneron and Teva to bar OA patients from fasinumab trials after US study halt
Advanced osteoarthritis patients will be barred from taking part in fasinumab trials after a sufferer enrolled in a Phase IIb study developed joint disease.
Archives for October 17, 2016
Pfizer: US Remicade biosimilar will launch at 15% discount in November
Pfizer’s Inflectra will become the first monoclonal antibody biosimilar available in the US when it is launched next month.
WuXi boosts cell therapy capacity with new PA facility
WuXi Apptec has opened a facility in Philadelphia offering chimeric antigen receptor T (CAR T) cell therapy manufacturing.
Recipharm commits SEK5m to bioanalysis lab citing lack of Nordic capacity
Recipharm has said it will spend SEK5m ($567,000) on a bioanalysis laboratory in Sweden citing the lack of capacity in the Nordic region as a driver for the investment.
Remsima and Inflectra not inferior to Remicade, NOR-SWITCH study finds
A two year-long Phase IV study has shown Celltrion’s infliximab biosimilar is not inferior to its originator Remicade, but a physician group still urges caution when switching.